Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Blood

• Publication date

  2003-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2002-09-2907PMID 12517814
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.

  2002cited by this paper
• RANK‐Fc in myeloma

  2002cited by this paper
• Elevated Level of Plasma Basic Fibroblast Growth Factor in Multiple Myeloma Correlates with Increased Disease Activity

  2002cited by this paper
• Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCα Activation*

  2002cited by this paper
• Syndecan-1 (CD138) Immunoreactivity in Bone Marrow Biopsies of Multiple Myeloma: Shed Syndecan-1 Accumulates in Fibrotic Regions

  2001cited by this paper
• Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.

  2001cited by this paper
• Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

  2001cited by this paper
• Vascular Endothelial Growth Factor (VEGF) -induced migration of Multiple Myeloma cells is associated with ββββ 1-integrin- and PI3-kinase- dependent PKC αααα activation

  2001cited by this paper
• Identification of a new fibroblast growth factor receptor, FGFR5.

  2001cited by this paper
• Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma

  2001cited by this paper
• Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.

  2001cited by this paper
• Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.

  2000cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Prognostic value of bone marrow angiogenesis in multiple myeloma.

  2000cited by this paper
• Structural interactions of fibroblast growth factor receptor with its ligands.

  2000cited by this paper
• Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

  2000influential reference
• Expression of the developmental markers STRO-1 and alkaline phosphatase in cultures of human marrow stromal cells: regulation by fibroblast growth factor (FGF)-2 and relationship to the expression of FGF receptors 1-4.

  2000cited by this paper
• Structural basis for FGF receptor dimerization and activation.

  1999cited by this paper
• Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.

  1999influential reference
• Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma

  1999influential reference
• Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.

  1999cited by this paper
• Antitumor activity of thalidomide in refractory multiple myeloma.

  1999cited by this paper
• Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.

  1999cited by this paper
• Receptor tyrosine kinase expression in human bone marrow stromal cells

  1998cited by this paper
• Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma.

  1998cited by this paper
• Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia.

  1998cited by this paper
• Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

  1997cited by this paper
• Signaling Vascular Morphogenesis and Maintenance

  1997cited by this paper
• Cytokine Flow Cytometry: Understanding Cytokine Biology at the Single-Cell Level

  1997cited by this paper
• Mechanisms of angiogenesis

  1997cited by this paper
• Nuclear Translocation of fibroblast growth factor (FGF) receptors in response to FGF-2

  1996cited by this paper
• Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.

  1996cited by this paper
• Blood vessel formation: what is its molecular basis?

  1996cited by this paper
• Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells.

  1996cited by this paper
• A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1

  1996cited by this paper
• Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.

  1995cited by this paper
• Interleukin-6 inhibits apoptosis of malignant plasma cells.

  1995cited by this paper
• Interleukin-6 in human multiple myeloma.

  1995cited by this paper
• Interleukin-6 prevents dexamethasone-induced myeloma cell death.

  1994cited by this paper
• Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures.

  1994cited by this paper
• Cell surface expression and functional significance of adhesion molecules on human myeloma‐derived cell lines

  1994cited by this paper
• Bone marrow angiogenesis and progression in multiple myeloma

  1994cited by this paper
• Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.

  1993cited by this paper
• Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin-6 production.

  1993cited by this paper
• Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

  1991cited by this paper
• 'Role of bone marrow stromal cells in the growth of human multiple myeloma.

  1991cited by this paper
• Characterization of the FGFR‐3 Gene and Its Gene Product

  1991cited by this paper
• Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase.

  1991cited by this paper
• The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma.

  1990cited by this paper
• Cloning and expression of two distinct high‐affinity receptors cross‐reacting with acidic and basic fibroblast growth factors.

  1990cited by this paper
• The role of interleukin‐1 and tumour necrosis factor‐α in human multiple myeloma

  1990cited by this paper
• Quantitation of mRNA by the polymerase chain reaction.

  1989cited by this paper
• Cytokine regulation of interleukin 6 production by human endothelial cells.

  1989cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• Nonparametric Statistics for the Behavioral Sciences. Sidney Siegel

  1959cited by this paper
• Nonparametric statistics for the behavioral sciences

  1956cited by this paper

• The Role of Macrophages in Pigmentary Disorders.

  2025cites this paper
• Role of the bone marrow microenvironment in multiple myeloma: Impact of niches on drug resistance mechanisms.

  2025cites this paper
• Combination of immune checkpoint inhibitors and anti-angiogenic agents: An emerging strategy for cancer therapy.

  2025cites this paper
• Angiogenesis in Multiple Myeloma: 25 Years of Research in This Field

  2025influential citation
• Discovery of novel FGF trap small molecules endowed with anti-myeloma activity.

  2024cites this paper
• The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma

  2024cites this paper
• Molecular and immunological mechanisms of clonal evolution in multiple myeloma

  2023cites this paper
• Mitochondrial dysfunction and drug targets in multiple myeloma

  2023cites this paper
• The roles of bone remodeling in normal hematopoiesis and age-related hematological malignancies

  2023cites this paper
• Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications.

  2022cites this paper
• Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling

  2021cites this paper
• FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation–Induced Mitochondrial Oxidative Stress

  2020cites this paper
• Current Understanding of Myelomatous Mesenchymal Stromal Cells Extended through Advances in Experimental Methods

  2020cites this paper
• Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma

  2020cites this paper
• FGF trapping impairs multiple myeloma growth through c-Myc degradation-induced mitochondrial oxidative stress

  2019cites this paper
• Is interleukin‐6 receptor blockade (tocilizumab) beneficial or detrimental to pig‐to‐baboon organ xenotransplantation?

  2019cites this paper
• Ganoderma lucidum polysaccharide reduces melanogenesis by inhibiting the paracrine effects of keratinocytes and fibroblasts via IL‐6/STAT3/FGF2 pathway

  2019influential citation
• Angiogenesis and Antiangiogenesis in Multiple Myeloma Angiogenesis and Antiangiogenesis in Multiple Myeloma

  2019cites this paper
• Game Theory of Tumor-Stroma Interactions in Multiple Myeloma: Effect of Nonlinear Benefits

  2018cites this paper
• Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?

  2018cites this paper
• Role of Jagged in multiple myeloma-associated angiogenesis

  2018influential citation
• Angiogenesis and Antiangiogenesis in Multiple Myeloma

  2018cites this paper
• Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells

  2018cites this paper
• Basic Fibroblast Growth Factor Regulates REX1 Expression Via IL‐6 In Stem Cells Isolated From Human Exfoliated Deciduous Teeth

  2017influential citation
• Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression

  2017cites this paper
• Tumor microenvironment and therapeutic response.

  2017cites this paper
• Rôle de la molécule APRIL dans le développement des hémopathies malignes B

  2017cites this paper
• Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model

  2017cites this paper
• Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy.

  2016cites this paper
• Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies

  2016influential citation
• Functional Interference in the Bone Marrow Microenvironment by Disseminated Breast Cancer Cells

  2016cites this paper
• Single cell functional analysis of multiple myeloma cell populations correlates with diffusion profiles in static microfluidic coculture systems.

  2016cites this paper
• Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity.

  2016cites this paper
• Silence of bFGF enhances chemosensitivity of glioma cells to temozolomide through the MAPK signal pathway.

  2016cites this paper
• Rapid Extensive Recurrence of Triple Negative Breast Cancer: Are Both Therapy and Cancer Biology the Culprit?

  2015cites this paper
• Mesenchymal stem cells derived from low risk acute lymphoblastic leukemia patients promote NK cell antitumor activity.

  2015cites this paper
• Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis

  2014cites this paper
• Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma

  2014cites this paper
• Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis

  2014cites this paper
• Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis

  2014cites this paper
• Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma

  2014cites this paper
• Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma

  2014cites this paper
• Human umbilical cord blood-derived stromal cells: A new resource for the proliferation and apoptosis of myeloma cells

  2014cites this paper
• [Tumor microenvironment and therapeutic resistance process].

  2014cites this paper
• Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis

  2014cites this paper
• Angiogenesis in multiple myeloma.

  2014cites this paper
• Le nt tumoral résistance

  2014cites this paper
• Role of brain-derived neurotrophic factor in bone marrow angiogenesis in multiple myeloma

  2013cites this paper
• induction of apoptosis in cytogenetically defined subgroups myeloma: abrogation of stroma-derived interleukin-6 secretion and Targeting receptor kinases by a novel indolinone derivative in multiple

  2013cites this paper
• activity with disease progression in myeloma: evidence favoring loss of marrow angiogenesis inhibitory Bone marrow angiogenic ability and expression of angiogenic cytokines

  2013cites this paper
• Use of in vitro primary culture models to investigate the activity of standard and novel therapies in haematological malignancies

  2013cites this paper
• Targeting Multiple Myeloma Tumor Angiogenesis: Focus on VEGF

  2013cites this paper
• The Proinflammatory Cytokine, IL-6, and its Interference with bFGF Signaling and PSMA in Prostate Cancer Cells

  2013cites this paper
• Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction

  2013cites this paper
• The evaluation of angiogenesis and matrix metalloproteinase-2 secretion in bone marrow of multiple myeloma patients before and after the treatment.

  2013cites this paper
• microenvironment migration of multiple myeloma cells in the bone marrow GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and

  2013cites this paper
• The mesenchymal tumor microenvironment

  2012cites this paper
• Structure and function of the solid tumor niche.

  2012cites this paper
• Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma

  2012cites this paper
• Novel vaccine adjuvant LPS-Hydrogel for truncated basic fibroblast growth factor to induce antitumor immunity.

  2012cites this paper
• Targeted Inhibition of Multiple Proinflammatory Signalling Pathways for the Prevention and Treatment of Multiple Myeloma

  2012cites this paper
• Neovascular Niche for Human Myeloma Cells in Immunodeficient Mouse Bone

  2012cites this paper
• From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma

  2011cites this paper
• Novel drugs in myeloma: harnessing tumour biology to treat myeloma.

  2011cites this paper
• HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients

  2011cites this paper
• The role of toll-like receptor mediated signalling in the pathogenesis of multiple myeloma.

  2011cites this paper
• Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.

  2011cites this paper
• Targeting the TumorMicroenvironment for Enhancing Chemotherapy in HematologicMalignancies

  2011cites this paper
• Angiogenesis and Multiple Myeloma

  2011cites this paper
• The microenvironment and molecular biology of the multiple myeloma tumor.

  2011cites this paper
• Novel therapies in MM: from the aspect of preclinical studies

  2011cites this paper
• Biological aspects of angiogenesis in multiple myeloma

  2011influential citation
• Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays

  2010cites this paper
• UvA-DARE ( Digital Academic Repository ) Heparan sulfate proteoglycans in B cell maturation and myeloma plasma cell survival

  2010influential citation
• Heparan sulfate proteoglycans in B cell maturation and myeloma plasma cell survival

  2010cites this paper
• Osteoclasts are important for bone angiogenesis.

  2010cites this paper
• Targeting the microenvironment

  2010cites this paper
• The proteasome inhibitor bortezomib inhibits FGF‐2‐induced reduction of TAZ levels in osteoblast‐like cells

  2010cites this paper
• Environment-mediated drug resistance: a major contributor to minimal residual disease

  2009cites this paper
• Apoptosis and the Tumor Microenvironment in Hematologic Malignancies

  2009cites this paper
• Multiple myeloma bone marrow niche.

  2009cites this paper
• The role of fibroblast growth factors in tumor growth.

  2009cites this paper
• CD28: old dog, new tricks. CD28 in plasma cell/multiple myeloma biology.

  2009cites this paper
• Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3–Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma

  2009cites this paper
• prognostic relevance of the expression of its receptor The role of IGF-1 as a major growth factor for myeloma cell lines and the

  2009cites this paper
• The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

  2009cites this paper
• Apoptosis in Carcinogenesis and Chemotherapy

  2009cites this paper
• The role of the insulin-like growth factor 1 receptor axis in multiple myeloma

  2009cites this paper
• Peripheral T‐cell lymphoma presenting as myelofibrosis with the expression of basic fibroblast growth factor

  2009cites this paper
• Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells

  2008cites this paper
• Novel anti-myeloma agents and angiogenesis

  2008cites this paper
• Regulation of tumor-stromal fibroblast interactions: implications in anticancer therapy.

  2008cites this paper
• The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance

  2008cites this paper
• Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.

  2008cites this paper
• The Role of the Bone Marrow Microenvironment in the Pathogenesis of Multiple Myeloma

  2007cites this paper
• Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis.

  2007cites this paper
• Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells

  2007influential citation
• Extravasation and homing mechanisms in multiple myeloma

  2007cites this paper
• Immunology at The University of Iowa

  2007cites this paper
• Promising New Agents in Phase I and II Clinical Trials in Multiple Myeloma

  2007cites this paper